IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum
- 19 October 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 75 (16) , 1423-1427
Abstract
Background: Interferon-β-1b (IFNβ-1b) has been used to prevent exacerbation of relapsing-remitting multiple sclerosis (RRMS) including optic-spinal multiple sclerosis (OSMS) in Japan. We encountered 2 patients with OSMS with unexpectedly severe exacerbation soon after the initiation of IFNβ-1b therapy. The experience urged us to retrospectively review the patients with RRMS who had been treated with IFNβ-1b to identify similar cases. Methods: At neurologic departments of 9 hospitals, the medical records of 56 patients with RRMS were reviewed to identify those who showed severe exacerbation soon after the initiation of IFNβ-1b therapy. Results: Of 56 patients with RRMS, we identified 7 who experienced severe exacerbation (exacerbation with increased scores of Expanded Disability Status Scale ≧7.0) within 90 days of the initiation of IFNβ-1b therapy. In all 7 patients, the exacerbations after the initiation of IFNβ-1b therapy were more severe than those experienced by the individual patients before the use of IFNβ-1b, and seemed to have occurred unexpectedly in a short time after the initiation of INFβ-1b therapy. A retrospective analysis revealed that all 7 patients had antibodies toward aquaporin 4, and the clinical features of all 7 patients after the exacerbation were consistent with those of neuromyelitis optica (NMO) spectrum. Conclusions: Our study suggests that IFNβ-1b may trigger severe exacerbation in patients with the NMO spectrum. In INFβ-1b therapy, cases in NMO spectrum should be carefully excluded.Keywords
This publication has 25 references indexed in Scilit:
- Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunityBrain, 2008
- Neuromyelitis optica: Changing conceptsJournal of Neuroimmunology, 2007
- Rethinking Neuromyelitis Optica (Devic Disease)Journal of Neuro-Ophthalmology, 2007
- Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelinationJournal of the Neurological Sciences, 2007
- Syndromes and complications of interferon therapyCurrent Opinion in Rheumatology, 2007
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelJournal of Experimental Medicine, 2005
- Development of myasthenia gravis in two patients with multiple sclerosis following interferon treatmentJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1aAnnals of Neurology, 2003
- Neuromyelitis OpticaSeminars in Neurology, 2002
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983